Core Insights - The article discusses the rising interest in terahertz wellness devices, particularly LION Care, which offers non-invasive solutions for sleep and recovery in 2025 [3][5][9] - LION Care emphasizes transparency, design integrity, and user experience, aligning with consumer demand for accessible wellness tools [10][14][36] Group 1: Market Trends - The global wellness market in 2025 is characterized by a strong consumer drive towards advanced, non-invasive technologies that complement self-directed health routines [5][8] - Significant increases in search queries related to terahertz healing and sleep recovery devices indicate growing public curiosity [6][8] - The performance optimization movement among athletes and professionals is encouraging the adoption of tools that enhance rest quality [8][36] Group 2: LION Care's Approach - LION Care positions its devices as part of a larger movement towards accessible recovery tools, focusing on design integrity and user experience [10][12][14] - The brand avoids making medical claims, reinforcing that its products are complementary tools within a broader wellness approach [13][46] - LION Care's design emphasizes ease of integration into existing relaxation routines, appealing to consumers seeking simplicity [11][14] Group 3: Technology and Consumer Engagement - Terahertz technology is increasingly discussed in wellness forums and social media, reflecting public curiosity about its potential benefits [16][17] - Influencer-driven content on platforms like TikTok normalizes the use of advanced technology in self-care routines [18][24] - Podcasts in the biohacking and wellness space are bringing visibility to terahertz devices, often discussing them alongside other non-invasive modalities [7][23] Group 4: Target Audience - LION Care appeals to various consumer segments, including wellness enthusiasts, high-performance professionals, athletes, sleep-focused consumers, and tech adopters [26][30][32] - The common thread among these groups is curiosity about how terahertz technology can enhance personal well-being [33] Group 5: Public Perception and Debate - The public conversation around terahertz devices is vibrant yet divided, with both supportive signals and skepticism present [37][38] - Supporters appreciate the non-invasive nature and convenience of terahertz devices, while critics highlight the lack of large-scale clinical research [39][40] - Neutral observers conduct extensive personal research before purchasing, valuing clear product descriptions and realistic expectations [41][42] Group 6: Industry Evolution - The wellness and performance technology market is evolving rapidly, driven by consumer demand for accessible and non-invasive solutions [34][35] - LION Care's entry into the terahertz category reflects broader trends towards integrating technology into wellness routines [36]

Core Viewpoint - U.S. Global Investors, Inc. has successfully listed its shipping ETF, the U.S. Global Sea to Sky Cargo ETF (SEA), on the Mexican Stock Exchange, expanding its international presence and providing investors with access to the global transportation and logistics sectors [1][3]. Company Overview - U.S. Global Investors, Inc. is a registered investment advisory firm with over 50 years of history, focusing on niche markets globally [5]. - The company specializes in gold mining stocks and the airline industry, and now aims to enhance its offerings in the shipping sector through the SEA ETF [1][5]. ETF Details - The SEA ETF is the first pure-play maritime shipping and air freight ETF listed on the BMV, joining the U.S. Global Jets ETF (JETS) and U.S. Global GO GOLD and Precious Metal Miners ETF (GOAU) [2][4]. - Launched in January 2022, SEA aims to provide diversified access to the global shipping and air freight industries, utilizing a Smart Beta 2.0 strategy to identify efficient companies in these sectors [4][13]. Market Context - The Bolsa Mexicana de Valores (BMV) is the second-largest stock exchange in Latin America, with a market capitalization exceeding $530 billion, indicating a significant opportunity for investment in the region [3]. - The Mexican government is investing billions to modernize its seaports, which aligns with SEA's focus on global trade expansion, particularly between North America and East Asia [4][3]. Industry Insights - Over 80% of global goods are transported by sea, highlighting the critical role of the companies within SEA's index in global commerce [5]. - The U.S. Global Sea to Sky Cargo Index (SEAX) tracks companies involved in marine shipping, air freight, and port operations, providing diversified exposure across various market capitalizations [13].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fiserv, Inc. common stock between July 24, 2024, and July 22, 2025, of the September 22, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1][2] Group 1: Class Action Details - A class action lawsuit has been filed against Fiserv, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To join the class action, investors can submit a form or contact the law firm for more information [2][5] - The lawsuit claims that Fiserv made false and misleading statements regarding its Clover platform and the forced migration of Payeezy merchants, which concealed a slowdown in new merchant business [4] Group 2: Allegations Against Fiserv - The lawsuit alleges that Fiserv's Clover platform experienced temporary revenue growth due to forced conversions from the Payeezy platform, masking underlying issues [4] - It is claimed that many former Payeezy merchants switched to competing solutions due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's growth [4] - The lawsuit asserts that Fiserv's positive statements about Clover's growth strategies and business prospects were materially false and misleading [4] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] - Founding partner Laurence Rosen has been recognized as a Titan of Plaintiffs' Bar by Law360, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3]

Core Insights - The article emphasizes the importance of conducting personal in-depth research and due diligence before making investment decisions, highlighting the inherent risks involved in trading [3]. Group 1 - The analysis is intended for informational purposes only and should not be considered as professional investment advice [3]. - There is a clear disclaimer regarding the lack of any stock, option, or similar derivative positions in the companies mentioned, indicating a neutral stance [2]. - The article expresses that past performance does not guarantee future results, reinforcing the need for careful consideration by investors [4].

For the quarter ended June 2025, Sotera Health Company (SHC) reported revenue of $294.34 million, up 6.4% over the same period last year. EPS came in at $0.20, compared to $0.19 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $276.08 million, representing a surprise of +6.61%. The company delivered an EPS surprise of +17.65%, with the consensus EPS estimate being $0.17.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wa ...

NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Flywire Corporation (NASDAQ: FLYW) between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), of the important September 23, 2025 lead plaintiff deadline. SO WHAT: If you purchased Flywire securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, and the lead plaintiff deadline is August 25, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Hims & Hers Health, Inc. made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo and the implications for its subscribers' access to Wegovy and compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages as a result of these misleading statements [4]

Core Insights - Iovance Biotherapeutics reported a wider loss of $0.33 per share for Q2 2025, exceeding the Zacks Consensus Estimate of a loss of $0.29, while revenues increased by 93% year-over-year to $60 million, falling short of the expected $66.4 million [1][10] Financial Performance - The company generated $54.1 million from Amtagvi sales, up from $43.6 million in the previous quarter, surpassing both the Zacks Consensus Estimate of $53.3 million and the internal estimate of $53.5 million, with over 100 patients infused during the quarter [3] - Proleukin contributed $5.9 million in sales, a decline of 68% year-over-year, missing the Zacks Consensus Estimate and internal estimates of $18 million [4] Operating Costs - Research and development expenses rose to $79.4 million, a 28% increase from the previous year, primarily due to higher employee and clinical costs [5] - Selling, general, and administrative expenses decreased by 5% to $37.7 million, attributed to lower stock compensation expenses [5] Guidance and Strategic Initiatives - Iovance maintained its product revenue guidance for the year, projecting revenues between $250 million and $300 million, driven by strong demand for its marketed products [6] - The company announced a strategic restructuring plan aimed at saving over $100 million annually, which includes laying off nearly 19% of its workforce [7] Cash Management and Future Outlook - Iovance expects net cash burn to be less than $245 million over the next four quarters, with cost savings extending the cash runway into Q4 2026 [8] - The company anticipates significant growth in total product revenues for 2026 and beyond, with gross margins expected to improve through optimization of manufacturing capacity [8] Regulatory Developments - Iovance has withdrawn its regulatory filing for Amtagvi in the European Union due to data alignment issues with the EMA, while applications in the UK, Canada, and Australia are under review [11][12] - The company is evaluating Amtagvi in combination with Merck's Keytruda in a phase III study for advanced melanoma, which will also serve as a confirmatory study for full approval [16] Stock Performance - Shares of Iovance fell nearly 29% in after-market trading following the news of the EU filing withdrawal, contributing to a year-to-date decline of 64% compared to a 1% decline in the industry [12][14]

ETFs that follow the tech-saturated Nasdaq 100 surged to record-time highs on Thursday, despite the U.S. imposing its broadest tariff increase in nearly 100 years.QQQ is hovering around its all-time highs. Track live prices here.Leading the pack were:Invesco QQQ Trust QQQInvesco NASDAQ 100 ETF QQQMDirexion NASDAQ 100 Equal Weighted Index Shares QQQEThese ETFs have bucked rising geopolitical tensions and a surge in trade-related uncertainty, reflecting investor confidence in the stability of big-cap U.S. tec ...

NuScale remains a speculative, long-term-only investment prospect -- and yesterday's earnings didn't matter at all.Nuclear power start-up stock NuScale Power (SMR -11.21%) disappointed investors with its second-quarter financial report last night, and the stock is down 8.2% through 12:15 p.m. Friday.Heading into the report, analysts forecast NuScale would generate about $11.7 million in revenue but remain unprofitable. Actual revenue was only $8.1 million, however, and NuScale lost $0.13 per share. NuScale ...